Arbutus Biopharma (ABUS) Reports In-Line Q2 EPS

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• LiveOne posts $19.4M revenue in Q1 fiscal 2027, narrows net loss
• Terreno Realty Corp (TRNO) PT Raised to $75 at KeyBanc on 'Improving Demand'